Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

被引：0
|
作者：
Thomas Semrad
Afsaneh Barzi
Heinz-Josef Lenz
Irene M. Hutchins
Edward J. Kim
I-Yeh Gong
Michael Tanaka
Laurel Beckett
William Holland
Rebekah A. Burich
Leslie Snyder-Solis
Philip Mack
Primo N. Lara
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology, Department of Internal Medicine
[2] University of Southern California Norris Cancer Center,Medical Oncology, Keck School of Medicine
[3] University of California,Department of Internal Medicine
[4] Davis,Division of Biostatistics, Department of Public Health Sciences
[5] University of California,undefined
[6] Davis,undefined
来源：
International Journal of Clinical Oncology | 2015年 / 20卷
关键词：
Gemcitabine; Erlotinib; Pancreatic cancer; Pharmacodynamic separation; KRAS mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：518 / 524
页数：6
相关论文
共 50 条
  • [1] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
    Semrad, Thomas
    Barzi, Afsaneh
    Lenz, Heinz-Josef
    Hutchins, Irene M.
    Kim, Edward J.
    Gong, I-Yeh
    Tanaka, Michael
    Beckett, Laurel
    Holland, William
    Burich, Rebekah A.
    Snyder-Solis, Leslie
    Mack, Philip
    Lara, Primo N., Jr.
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 518 - 524
  • [2] Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer
    Khatri, P.
    Kumari, P.
    Beniwal, S.
    Samdariya, S.
    ANNALS OF ONCOLOGY, 2016, 27 : 92 - 92
  • [3] EFFICACY AND POSSIBLE BIOMARKER OF GEMCITABINE AND ERLOTINIB FOR ADVANCED PANCREATIC CANCER
    Takahashi, Hideaki
    Kuwahara, Akiko
    Okuyama, Hiroyuki
    Ohno, Izumi
    Shimizu, Satoshi
    Mitsunaga, Shuichi
    Shinohara, Akira
    Kobayashi, Misaki
    Okusaka, Takuji
    Ikeda, Masafumi
    ANNALS OF ONCOLOGY, 2014, 25
  • [4] A phase II study of isoflavone, gemcitabine, and erlotinib in locally advanced (LA) or metastatic pancreatic cancer
    Hammad, N.
    Philip, P. A.
    Shields, A. F.
    Sarkar, F. H.
    Abruzzese, J. L.
    Kaseb, A. O.
    Javle, M. M.
    Varadhachary, G. R.
    Wolff, R. A.
    El-Rayes, B. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer
    Danese, Mark D.
    Reyes, Carolina
    Northridge, Kelly
    Lubeck, Deborah
    Lin, Chin-Yu
    O'Connor, Paula
    CLINICAL THERAPEUTICS, 2008, 30 (04) : 775 - 784
  • [6] Gemcitabine and oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer
    All, M.
    Carillio, G.
    Mazzola, A.
    Bagnato, S.
    Di Leo, M. G.
    Fallica, G.
    Anna, Aiello R.
    Chiarenza, M.
    Caruso, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI52 - XI52
  • [7] Chemoradiotherapy after gemcitabine plus erlotinib in patients with locally advanced pancreatic cancer
    Kim, Eunji
    Kim, Kyubo
    Chie, Eui Kyu
    Oh, Do-Youn
    Kim, Yong Tae
    JOURNAL OF BUON, 2017, 22 (04): : 1046 - 1052
  • [8] Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
    Wang, Yuan
    Hu, Guo-fang
    Zhang, Qian-qian
    Tang, Ning
    Guo, Jun
    Liu, Li-yan
    Han, Xiao
    Wang, Xia
    Wang, Zhe-hai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1961 - 1972
  • [9] Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients
    Samelis, Georgios F.
    Ekmektzoglou, Konstantinos
    Tsiakou, Andriani
    Giannakaki, Styliani
    Konstadoulakis, Manoussos
    HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1776 - 1781
  • [10] A randomized phase II clinical trial of gemcitabine, oxaliplatin, erlotinib combination chemotherapy versus gemcitabine and erlotinib in previously untreated patients with locally advanced or metastatic pancreatic cancer.
    Lim, Sung Hee
    Yun, Jina
    Lee, Min-Young
    Kim, Han Jo
    Kim, Kyoung Ha
    Kim, Se Hyung
    Lee, Sang-Cheol
    Bae, Sang Byung
    Kim, Chan Kyu
    Lee, Namsu
    Lee, Kyu Taek
    Park, Sung Kyu
    Hong, Dae Sik
    Choi, Hyun Jong
    Moon, Jong Ho
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345